Transcription of ETEC Vaccine Strategies - WHO
{{id}} {{{paragraph}}}
Example: stock market
ETEC Vaccine Strategies - WHO
C E N T E R F O R V A C C I N E I N N O V A T I O N A N D A C C E S S path /Gabe Bienczycki Status of Vaccine Development for ETEC and Shigella Presentation to WHO Product Development for Vaccine Advisory Committee (PDVAC) 22 June 2017 Geneva, Switzerland A. Louis Bourgeois, PhD, MPH Scientific Director Enteric Vaccine Initiative Presentation overview Dynamic field with priorities in transition; high level of activity and progress since PDVAC 2016 ETEC and Shigella disease burden debate and implications on Vaccine development Overview of recent WHO ETEC/Shigella burden consultation April 2017 Standalone vaccines versus combination product considerations Technical feasibility, Clinical data and Funding; Risk and Time of development Updates on most advanced candidates with emphasis on progress since last PDVAC Mtg. Highlights from other WHO and path sponsored meetings on ETEC and Shigella vaccines path diarrheal disease severity score workshop March 2016 (Wierzba et al.)
CENTER FOR VACCINE INNOVATION AND ACCESS PATH/Gabe Bienczycki Status of Vaccine Development for ETEC and Shigella Presentation to WHO Product Development
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Related search queries
ANNUAL REPORT, Path, History I: Advanced Placement, History I Advanced Placement, Critical, United Nations Conference on Trade and, United Nations Conference on Trade and Development, Harvard managementor, Power of Cross-Functional Teams, Education and Training Sector Improvement, Education and Training Sector Improvement Programme ETSIP, The Back to Basics concept